Advances in the study of molecular mechanisms, applications and screening for altered peptide ligand.
- Author:
Qing-Qing WANG
1
;
Hong-Zhen YANG
;
Zhuo-Wei HU
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antigen-Presenting Cells;
immunology;
metabolism;
Autoimmune Diseases;
immunology;
therapy;
Humans;
Immunotherapy;
methods;
Ligands;
Major Histocompatibility Complex;
immunology;
Peptide Fragments;
biosynthesis;
immunology;
metabolism;
therapeutic use;
Peptide Library;
Receptors, Antigen, T-Cell;
immunology;
metabolism
- From:
Acta Pharmaceutica Sinica
2008;43(2):113-117
- CountryChina
- Language:Chinese
-
Abstract:
Altered peptide ligand (APL), a short peptide with immune regulatory activity and substitutions of a single or multiple amino acids in an antigenic peptide, has shown potential therapeutic effect on autoimmune disease, tumor and virus infection. APL regulates immune responses by interfering the interaction between the major histocompatibility complex (MHC), antigenic peptide and T cell receptor (TCR), or by regulating the intracellular signaling of antigen presenting cells, bystander suppression and inducing heterogenous immune responses. High-specific and high-affinity APL screened from peptide laboratory by phage display, has a potential to be a new resource for drug with antigen specificity.
